Evelo Biosciences Analyst Ratings
Evelo Biosciences Analyst Ratings
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $2.00 to $10.00. The current price Evelo Biosciences (EVLO) is trading at is $7.47, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/26/2023 | 33.87% | Morgan Stanley | $2 → $10 | Maintains | Equal-Weight |
| 02/15/2023 | -73.23% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 11/16/2022 | -66.53% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | -46.45% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | -33.07% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | -33.07% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 455.56% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 60.64% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 408.7% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 274.83% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 74.03% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 140.96% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 87.42% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 261.45% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | -19.68% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 7.1% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 181.12% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | -19.68% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 140.96% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 33.87% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
| 10/12/2018 | 301.61% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 10/11/2018 | 301.61% | Morgan Stanley | $29 → $30 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/26/2023 | 33.87% | 摩根士丹利 | 2 美元 → 10 美元 | 维护 | 重量相等 |
| 02/15/2023 | -73.23% | 摩根士丹利 | 4 美元 → 2 美元 | 维护 | 重量相等 |
| 11/16/2022 | -66.53% | 查丹资本 | → 2.5 美元 | 降级 | 买入 → 中性 |
| 09/09/2022 | -46.45% | 摩根士丹利 | 5 美元 → 4 美元 | 维护 | 重量相等 |
| 2022 年 8 月 24 日 | -33.07% | 摩根士丹利 | 6 美元 → 5 美元 | 维护 | 重量相等 |
| 08/15/2022 | -33.07% | 查丹资本 | 12 美元 → 5 美元 | 维护 | 购买 |
| 11/02/2021 | 455.56% | JMP 证券 | 44 美元 → 41.5 美元 | 维护 | 市场跑赢大盘 |
| 11/01/2021 | 60.64% | 查丹资本 | → 12 美元 | 升级 | 中性 → 买入 |
| 06/23/2021 | 408.7% | JMP 证券 | 36 美元 → 38 美元 | 维护 | 市场跑赢大盘 |
| 06/23/2021 | 274.83% | 坎托·菲茨杰拉德 | → 28 美元 | 启动覆盖开启 | → 超重 |
| 05/03/2021 | 74.03% | 摩根士丹利 | 14 美元 → 13 美元 | 维护 | 重量相等 |
| 2021 年 12 月 4 日 | 140.96% | 杰富瑞 | 11 美元 → 18 美元 | 升级 | 持有 → 买入 |
| 2021 年 1 月 19 日 | 87.42% | 摩根士丹利 | 6 美元 → 14 美元 | 维护 | 重量相等 |
| 2020 年 12 月 23 日 | 261.45% | JMP 证券 | → 27 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 11/11/2020 | -19.68% | 摩根士丹利 | 8 美元 → 6 美元 | 维护 | 重量相等 |
| 05/21/2020 | 7.1% | 摩根士丹利 | → 8 美元 | 降级 | 超重 → 重量相等 |
| 05/12/2020 | 181.12% | BMO 资本 | 24 美元 → 21 美元 | 维护 | 跑赢大盘 |
| 05/12/2020 | -19.68% | 杰富瑞 | 18 美元 → 6 美元 | 降级 | 买入 → 持有 |
| 2019 年 4 月 30 日 | 140.96% | 杰富瑞 | → 18 美元 | 启动覆盖开启 | → 购买 |
| 2019 年 1 月 29 日 | 33.87% | 查丹资本 | → 10 美元 | 启动覆盖开启 | → 中立 |
| 2018 年 12 月 10 日 | 301.61% | 摩根士丹利 | 29 美元 → 30 美元 | 维护 | 超重 |
| 10/11/2018 | 301.61% | 摩根士丹利 | 29 美元 → 30 美元 | 维护 | 超重 |
What is the target price for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的目标价格是多少？
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by Morgan Stanley on July 26, 2023. The analyst firm set a price target for $10.00 expecting EVLO to rise to within 12 months (a possible 33.87% upside). 6 analyst firms have reported ratings in the last year.
摩根士丹利于2023年7月26日公布了Evelo Biosciences（纳斯达克股票代码：EVLO）的最新目标股价。这家分析公司将目标股价定为10.00美元，预计EVLO将在12个月内升至10.00美元（可能上涨33.87％）。去年有6家分析公司公布了评级。
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的最新分析师评级是多少？
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by Morgan Stanley, and Evelo Biosciences maintained their equal-weight rating.
Evelo Biosciences（纳斯达克股票代码：EVLO）的最新分析师评级由摩根士丹利提供，Evelo Biosciences维持其同等权重评级。
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Evelo Biosciences（EVLO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on July 26, 2023 so you should expect the next rating to be made available sometime around July 26, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Evelo Biosciences的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Evelo Biosciences的最后一次评级是在2023年7月26日提交的，因此你应该预计下一个评级将在2024年7月26日左右公布。
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
分析师对 Evelo Biosciences (EVLO) 的评级正确吗？
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a maintained with a price target of $2.00 to $10.00. The current price Evelo Biosciences (EVLO) is trading at is $7.47, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Evelo Biosciences（EVLO）评级维持不变，目标股价为2.00美元至10.00美元。Evelo Biosciences（EVLO）目前的交易价格为7.47美元，在分析师的预测区间内。
